PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from strong segmental performance.
PerkinElmer (PKI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
PerkinElmer (PKI) delivered earnings and revenue surprises of 17.43% and 9.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment.
PerkinElmer (PKI) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
PerkinElmer (PKI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If You Invested $1000 in PerkinElmer 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Catalent (CTLT) to Enhance Its Portfolio via RheinCell Buyout
by Zacks Equity Research
Catalent (CTLT) expects to strengthen its position in new therapeutic areas and boost its cell therapy portfolio via the latest acquisition.
Here's How Investors Can Find Strong Computer and Technology Stocks with the Zacks ESP Screener
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Agilent (A) Expands Presence in LC Market With New Systems
by Zacks Equity Research
Agilent (A) expands its Bio Liquid Chromatography solutions portfolio with three new systems to fulfil the needs of biopharma industry.
PerkinElmer (PKI) to Boost Portfolio via SIRION Acquisition
by Zacks Equity Research
PerkinElmer (PKI) expects to be able to support its cell and gene therapy workflows, and expand its existing research solutions via the latest buyout.
If You Invested $1000 in PerkinElmer a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
PerkinElmer (PKI) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PerkinElmer (PKI) Gets COVID-19 Solutions Contract Extension
by Zacks Equity Research
PerkinElmer's (PKI) COVID-19 Lighthouse Laboratory contract extended through March 2022 to align with NHS Test and Trace's testing strategy.
Here's How Much a $1000 Investment in PerkinElmer Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp
by Zacks Equity Research
Zacks Industry Outlook Highlights: Mettler-Toledo International, PerkinElmer and Bruker Corp
3 Stocks to Watch on Rising Demand for Scientific Instruments
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), PerkinElmer (PKI) and Bruker Corporation (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand as well as rising healthcare spending.
LHC Group (LHCG) Forays Into Oregon With New Acquisition
by Zacks Equity Research
LHC Group (LHCG) acquires Home 'n Hospice to expand its existing footprint in Idaho.
PerkinElmer's (PKI) COVID-19 Test Kit Part of Investigative Study
by Zacks Equity Research
PerkinElmer's (PKI) test kit, which is currently being used in an investigative study, is aimed at accelerating the vaccine development and treatments against COVID-19.
PerkinElmer (PKI) to Boost Immunodiagnostics Unit With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire IDS, which will enable the former to grow its overall Diagnostics business, particularly its immunodiagnostics unit.
If You Invested $1000 in PerkinElmer a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
PerkinElmer (PKI) Boosts Cell Biology Portfolio With Buyout
by Zacks Equity Research
PerkinElmer (PKI) enters into an agreement to acquire Nexcelom that will enable the former to boost its efforts when it comes to solutions for drug discovery.
PerkinElmer (PKI) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
PerkinElmer (PKI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from strong segmental performance.